Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AMRX - Amneal Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.33
DETAILS
HIGH:
$19.00
LOW:
$16.00
MEDIAN:
$17.00
CONSENSUS:
$17.33
UPSIDE:
2.18%
Stock News
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations
MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens.
Why Amneal Pharmaceuticals (AMRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally? GF Value Says Overvalued
On June 10, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 4.4% today, bringing the current price to $15.32. This price is within a 52-week range that has
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire NASHVI
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hope announced the launch of its national "Hope Alliance" campaign this year, a strategic initiative designed to expand access to high-quality, longer-dated medications for low-income and uninsured patients across the United States.
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
Amneal Pharmaceuticals NASDAQ: AMRX Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches.
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amneal and Pfizer GLP-1 Deal: New Growth Lever?
AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.
Is Amneal a Buy Before Rytary Generic Erosion?
AMRX faces Rytary generic pressure in 2026, but growth in generics, injectables, biosimilars, and higher profitability targets could support its outlook.
What's Driving Amneal's 2026 Growth Outlook?
AMRX's 2026 outlook is driven by higher profit expectations, a steady launch cadence, and growth from complex generics, injectables, and specialty brands.
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, which are being presented at the Advanced Therapeutics in Movement & Related Disorders® (ATRMD) 2026 Congress on June 5, 2026.
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy (CGT) designation, giving Amneal 180 days of market exclusivity.
Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution
Amneal Pharmaceuticals (NASDAQ:AMRX) said on Thursday the US Food and Drug Administration has approved its romidepsin injection solution, 27.5 mg/5.5 mL, in...
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal's differentiated injectables portfolio BRIDGEWATER, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials.
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Price Targets
Amneal Pharmaceuticals price target raised to $16 from $15 at Barclays
$16.00
(was $11.81)
Glen Santangelo
·
Barclays
Amneal Pharmaceuticals initiated with a Buy at UBS
$19.00
(was $13.09)
Ashwani Verma
·
UBS
Amneal Pharmaceuticals (AMRX) PT Raised to $17; Truist: 'Stock pullback a great entry point'
$17.00
(was $13.45)
Les Sulewski
·
Truist Financial
Amneal Pharmaceuticals price target raised to $15 from $14 at Truist
$15.00
(was $12.99)
Truist Financial
Amneal Pharmaceuticals initiated with an Overweight at Barclays
$15.00
(was $11.87)
Barclays
Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays
$11.00
(was $8.76)
Barclays
Amneal Pharmaceuticals (AMRX) PT Raised to $11 at Piper Sandler
$11.00
(was $8.29)
David Amsellem
·
Piper Sandler
Amneal Pharmaceuticals price target raised to $12 from $10 at Truist
$12.00
(was $8.70)
Les Sulewski
·
Truist Financial
Truist Securities Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX)
$10.00
(was $8.70)
Les Sulewski
·
Truist Financial
Amneal Pharmaceuticals (AMRX) PT Raised to $9 at Truist Securities
$9.00
(was $6.76)
Les Sulewski
·
Truist Financial
Amneal Pharmaceuticals (AMRX) PT Raised to $8 at Piper Sandler
$8.00
(was $6.29)
David Amsellem
·
Piper Sandler
Goldman Sachs Maintains Buy on Amneal Pharmaceuticals, Lowers Price Target to $4
$4.00
(was $3.22)
Goldman Sachs